How much revenue does Renascience make?

Renascience reported 68.55 million JPY in revenue for fiscal year 2026, down 48.3% from 132.69 million JPY in fiscal year 2025.

What companies are similar to Renascience?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Menicon Co., Ltd. (7780.T), Seed Co.,Ltd. (7743.T), Fuso Pharmaceutical Industries,Ltd. (4538.T), Kubota Pharmaceutical Holdings Co., Ltd. (4596.T).

Renascience Inc. (4889.T) Stock

About Renascience Inc.

Renascience Inc. develops and sells pharmaceuticals, medical devices, and artificial intelligence (AI)-powered programmed medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angio-sarcoma, coronavirus lung injury, and interstitial lung disease ...

At a glance

Renascience reported revenue of 68.55 million JPY for fiscal year 2026, down 48.3% from fiscal year 2025, and net income of -301.28 million JPY.

Figures from company filings; latest fiscal year ended March 31, 2026.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.